Restricted accessResearch articleFirst published online 2025-08
Measuring Pre-Exposure Prophylaxis (PrEP) Stigma Among Adolescent Girls and Young Women in Western Kenya: Scale Development,Validation,and Associations with PrEP Adherence
Qualitative studies suggest stigma is a barrier to pre-exposure prophylaxis (PrEP) adherence among adolescent girls and young women (AGYW) in sub-Saharan Africa, but there are few quantitative data or validated measures available. This study sought to develop and validate a scale to measure PrEP stigma among AGYW in western Kenya. An initial scale was developed, then pilot tested with 200 AGYW taking PrEP. The final scale was used in a longitudinal study with 250 AGYW to assess the prevalence and sources of PrEP stigma and to test whether PrEP stigma is associated with PrEP adherence, measured by hair tenofovir levels. The pilot testing resulted in the final 17-item Young Women’s PrEP Stigma Scale (YW-PSS) with subscales for perceived, anticipated, experienced, and internalized PrEP stigma, high internal consistency (Cronbach’s alpha = 0.81), and evidence of divergent and construct validity. In the longitudinal study, 72% of participants reported any perceived PrEP stigma, 64% any anticipated stigma, 35% any experienced stigma, and 15% any internalized stigma. The most commonly reported stigma perpetrators were friends, male partners, and men and women from the community. Participants with higher total, perceived, or experienced PrEP stigma scores were significantly less likely to have high PrEP adherence, while anticipated and internalized stigma were not associated with PrEP adherence. Findings from this study support the validity and reliability of the YW-PSS among AGYW in Kenya and suggest that PrEP stigma is highly prevalent and predicts poor PrEP adherence. Stigma reduction interventions are needed to support PrEP adherence and well-being in this population.
Get full access to this article
View all access options for this article.
References
1.
UNAIDS. The Urgency of Now: AIDS at a Crossroads. 2024 Global AIDS Update. Joint United Nations Programme on HIV/AIDS: Geneva; 2024.
2.
FonnerVA, DalglishSL, KennedyCE, et al.Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS, 2016; 30(12):1973–1983; doi: 10.1097/QAD.0000000000001145
3.
MarrazzoJ, TaoL, BeckerM, et al.HIV Preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women. JAMA, 2024; 331(11):930–937; doi: 10.1001/jama.2024.0464
4.
ChouR, SpencerH, BougatsosC, et al.Preexposure prophylaxis for the prevention of HIV: Updated evidence report and systematic review for the US preventive services task force. JAMA, 2023; 330(8):746–763; doi: 10.1001/jama.2023.9865
5.
CelumCL, BukusiEA, BekkerLG, et al.PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa : The POWER demonstration project. J Int AIDS Soc, 2022:1–9; doi: 10.1002/jia2.25962/full
6.
TapsobaJDD, ZangenehSZ, AppelmansE, et al.Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care, 2021; 33(6):712–720; doi: 10.1080/09540121.2020.1822505
7.
MayanjaY, KamacookoO, LunkuseJF, et al.Oral pre‐exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: A prospective cohort study. J Int AIDS Soc, 2022; 25(5):e25909–e11; doi: 10.1002/jia2.25909
8.
OhiomobaRO, OwuorPM, OreroW, et al.Pre-Exposure Prophylaxis (PrEP) initiation and retention among young kenyan women. AIDS Behav, 2022; 26(7):2376–2386; doi: 10.1007/s10461-022-03576-x
9.
WereD, MusauA, MutegiJ, et al.Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: Results from a programmatic surveillance study. J Int AIDS Soc, 2020; 23 Suppl 3(Suppl 3):e25537–e77; doi: 10.1002/jia2.25537
10.
KinuthiaJ, PintyeJ, AbunaF, et al.; PrEP Implementation for Young Women and Adolescents (PrIYA) programme. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: Results from an implementation programme. Lancet HIV, 2020; 7(1):e38–e48; doi: 10.1016/S2352-3018(19)30335-2
11.
IrunguEM, MugwanyaKK, MugoNR, et al.; Partners Scale-Up Project Team. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: A pragmatic stepped-wedge randomised trial. Lancet Glob Health, 2021; 9(12):e1730–e1739; doi: 10.1016/S2214-109X(21)00391-0
12.
CelumC, SeidmanD, TravillD, et al.A decision support tool has similar high PrEP uptake and increases early PrEP persistence in adolescent girls and young women in South Africa: Results from a randomized controlled trial. J Int AIDS Soc, 2023; 26(8):e26154; doi: 10.1002/jia2.26154
13.
CelumC, HosekS, TsholwanaM, et al.PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med, 2021; 18(6):e1003670–e18; doi: 10.1371/journal.pmed.1003670
14.
CelumCL, GillK, MortonJ, et al.Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: A randomized trial. J Int AIDS Soc, 2020:1–10; doi: 10.1002/jia2.25636/full
15.
TapsobaJdD, CoverJ, Obong’oC, et al.Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. PLoS Med, 2022; 19(9):e1004097; doi: 10.1371/journal.pmed.1004097
16.
SweeneySM, VanablePA. The association of HIV-related stigma to HIV medication adherence: A systematic review and synthesis of the literature. AIDS Behav, 2016; 20(1):29–50; doi: 10.1007/s10461-015-1164-1
17.
KaneJC, ElafrosMA, MurraySM, et al.A scoping review of health-related stigma outcomes for high-burden diseases in low- and middle-income countries. BMC Med, 2019; 17(1):17; doi: 10.1186/s12916-019-1250-8
18.
LogieCH, OkumuM, Kibuuka MusokeD, et al.Intersecting stigma and HIV testing practices among urban refugee adolescents and youth in Kampala, Uganda: Qualitative findings. J Int AIDS Soc, 2021; 24(3):e25674; doi: 10.1002/jia2.25674
19.
Maughan-BrownB, NybladeL. Different dimensions of HIV-related stigma may have opposite effects on HIV testing: Evidence among young men and women in South Africa. AIDS Behav, 2014; 18(5):958–965; doi: 10.1007/s10461-013-0636-4
20.
GolubSA. PrEP Stigma: Implicit and explicit drivers of disparity. Curr HIV/AIDS Rep, 2018; 15(2):190–197; doi: 10.1007/s11904-018-0385-0
21.
VellozaJ, KhozaN, ScorgieF, et al.; HPTN 082 study group. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: A qualitative study. J Int AIDS Soc, 2020; 23(3):e25463–e10; doi: 10.1002/jia2.25463
22.
HerronPD. Ethical implications of social stigma associated with the promotion and use of pre-exposure prophylaxis for HIV prevention. LGBT Health, 2016; 3(2):103–108; doi: 10.1089/lgbt.2014.0114
23.
StanglAL, EarnshawVA, LogieCH, et al.The health stigma and discrimination framework : A global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med, 2019; 17(1):18–23; doi: 10.1186/s12916-019-1271-3
24.
TuranB, HatcherAM, WeiserSD, et al.Framing mechanisms linking HIV-related stigma, adherence to treatment, and health outcomes. Am J Public Health, 2017; 107(6):863–869; doi: 10.2105/AJPH.2017.303744
25.
MunthaliRJ, StanglAL, BaronD, et al.; EMPOWER study team. Prevalence and risk factors of PrEP use stigma among adolescent girls and young women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial. AIDS Behav, 2022; 26(12):3950–3962; doi: 10.1007/s10461-022-03721-6
26.
AtkinsK, KanL, MusauA, et al.Adaptation and psychometric evaluation of a scale to measure oral pre-exposure prophylaxis-related stigma among key and vulnerable populations in Kenya. J Int AIDS Soc, 2022; 25(Suppl 1):e25929; doi: 10.1002/jia2.25929
27.
AlmeidaA, OgbonnayaIN, WanyenzeRK, et al.A psychometric evaluation and a framework test of the HIV stigma mechanisms scale among a population-based sample of men and women living with HIV in Central Uganda. AIDS Behav, 2023; 27(9):3038–3052; doi: 10.1007/s10461-023-04026-y
28.
KayES, RiceWS, CrockettKB, et al.Experienced HIV-related stigma in health care and community settings: Mediated associations with psychosocial and health outcomes. J Acquir Immune Defic Syndr, 2018; 77(3):257–263; doi: 10.1097/QAI.0000000000001590
29.
BudhwaniH, Yiğitİ, Maragh-BassAC, et al.Development and validation of the youth Pre-Exposure Prophylaxis (PrEP) stigma scale. AIDS Behav, 2023; 27(3):929–938; doi: 10.1007/s10461-022-03829-9
30.
MustanskiB, RyanDT, HayfordC, et al.Geographic and individual associations with PrEP stigma: Results from the RADAR cohort of diverse young men who have sex with men and transgender women. AIDS Behav, 2018; 22(9):3044–3056; doi: 10.1007/s10461-018-2159-5
31.
WalshJL. Applying the information-motivation-behavioral skills model to understand PrEP intentions and use among men who have sex with men. AIDS Behav, 2019; 23(7):1904–1916; doi: 10.1007/s10461-018-2371-3
32.
CalabreseSK, DovidioJF, TekesteM, et al.HIV Pre-Exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr, 2018; 79(1):46–53; doi: 10.1097/QAI.0000000000001762
33.
GolubSA, FikslinRA, GoldbergMH, et al.Predictors of PrEP uptake among patients with equivalent access. AIDS Behav, 2019; 23(7):1917–1924; doi: 10.1007/s10461-018-2376-y
34.
SieglerAJ, WiatrekS, MouhannaF, et al.Validation of the HIV Pre-exposure prophylaxis stigma scale: Performance of likert and semantic differential scale versions. AIDS Behav, 2020; 24(9):2637–2649; doi: 10.1007/s10461-020-02820-6
35.
ChittamuruD, FryeV, KoblinBA, et al.PrEP stigma, HIV stigma, and intention to use PrEP among women in New York City and Philadelphia. Stigma Health, 2020; 5(2):240–246; doi: 10.1037/sah0000194
36.
CahillS, TaylorSW, ElsesserSA, et al.Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care, 2017; 29(11):1351–1358; doi: 10.1080/09540121.2017.1300633
37.
WoodS, GrossR, SheaJA, et al.Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav, 2019; 23(10):2719–2729; doi: 10.1007/s10461-019-02502-y
38.
KleinH, WashingtonTA. The Pre-Exposure Prophylaxis (PrEP) stigma scale: Preliminary findings from a pilot study. Int Public Health J, 2019; 11(2):185–195.
39.
JaniN, MathurS, KahabukaC, et al.Relationship dynamics and anticipated stigma: Key considerations for PrEP use among Tanzanian adolescent girls and young women and male partners. PLoS ONE, 2021; 16(2):e0246717–e16; doi: 10.1371/journal.pone.0246717
40.
HallK, ManuA, MorheE, et al.Understanding “Bad Girl:” qualitative findings on stigma and adolescent sexual and reproductive health in Ghana. Contraception, 2015; 92(4):393–394; doi: 10.1016/j.contraception.2015.06.158
41.
Mackworth-YoungCR, BondV, WringeA, et al.“My mother told me that I should not”: A qualitative study exploring the restrictions placed on adolescent girls living with HIV in Zambia. J Int AIDS Soc, 2017; 20(4):e25035–e8; doi: 10.1002/jia2.25035
42.
NybladeL, StocktonM, NyatoD, et al.Perceived, anticipated and experienced stigma: Exploring manifestations and implications for young people’s sexual and reproductive health and access to care in North-Western Tanzania. Cult Health Sex, 2017; 19(10):1092–1107; doi: 10.1080/13691058.2017.1293844
43.
HartmannM, OttichaS, AgotK, et al.Tu’Washindi na PrEP: Working with young women and service providers to design an intervention for PrEP uptake and adherence in the context of gender-based violence. AIDS Educ Prev, 2021; 33(2):103–119; doi: 10.1521/aeap.2021.33.2.103
44.
GoparajuL, PraschanNC, JeanpiereLW, et al.Stigma, partners, providers and costs: Potential barriers to PrEP uptake among US Women. J AIDS Clin Res, 2017; 8(9):730; doi: 10.4172/2155-6113.1000730
45.
PintyeJ, Beima-SofieKM, Makabong’oPA, et al.HIV-Uninfected Kenyan Adolescent and Young Women share perspectives on using pre-exposure prophylaxis during pregnancy. AIDS Patient Care STDS, 2018; 32(12):538–544; doi: 10.1089/apc.2018.0058
46.
EscuderoJN, DettingerJC, PintyeJ, et al.Community perceptions about use of pre-exposure prophylaxis among adolescent girls and young women in Kenya. J Assoc Nurses AIDS Care, 2020; 31(6):669–677; doi: 10.1097/JNC.0000000000000191
47.
HartmannM, NybladeL, OttichaS, et al.The development of a conceptual framework on PrEP stigma among adolescent girls and young women in sub-Saharan Africa. J Int AIDS Soc, 2024; 27(2):e26213; doi: 10.1002/jia2.26213
48.
YoungAM, MancusoN, AtujunaM, et al.Adolescent girls and young women’s experiences with disclosing oral PrEP or Dapivirine vaginal ring use: A multi-country qualitative analysis. AIDS Behav, 2023; 27(12):3941–3951; doi: 10.1007/s10461-023-04109-w
49.
Kenya Ministry of Health, National AIDS and STI Control Programme, and National AIDS Control Council., National AIDS and STI Control Programme, National AIDS Control Counci. Kenya HIV Estimates Report 2020. Ministry of Health: Nairobi, Kenya; 2020.
50.
BoatengGO, NeilandsTB, FrongilloEA, et al.Best practices for developing and validating scales for health, social, and behavioral research: A primer. Front Public Health, 2018; 6(June):149–118; doi: 10.3389/fpubh.2018.00149
51.
OttichaS, RobertsST, HartmannMA, et al.Engaging youth to conduct research among peers: Lessons from a PrEP study in Siaya County, Kenya. In: Presented at the 24th International AIDS Conference Montreal, Canada and virtually; 2022; Abstract EPD005.
52.
SaulJ, BachmanG, AllenS, et al.The DREAMS core package of interventions: A comprehensive approach to preventing HIV among adolescent girls and young women. PLoS ONE, 2018; 13(12):e0208167.
53.
HallKS, ManuA, MorheE, et al.Development and validation of a scale to measure adolescent sexual and reproductive health stigma: Results from young women in Ghana. J Sex Res, 2018; 55(1):60–72; doi: 10.1080/00224499.2017.1292493
54.
MacPhersonP, WebbEL, ChokoAT, et al.Stigmatising attitudes among people offered home-based HIV testing and counselling in blantyre, Malawi: Construction and analysis of a stigma scale. PLoS One, 2011; 6(10):e26814; doi: 10.1371/journal.pone.0026814
55.
LusenoWK, FieldSH, IritaniBJ, et al.Pathways to depression and poor quality of life among adolescents in Western Kenya: Role of anticipated HIV stigma, HIV risk perception, and sexual behaviors. AIDS Behav, 2021; 25(5):1423–1437; doi: 10.1007/s10461-020-02980-5
56.
WilliamsDR, YuY, JacksonJS, et al.Racial differences in physical and mental health. Socio-economic status, stress and discrimination. J Health Psychol, 1997; 2(3):335–351; doi: 10.1177/135910539700200305
57.
LogieCH, Lacombe-DuncanA, WangY, et al.Sexual orientation differences in health and wellbeing among women living with HIV in canada: Findings from a national cohort study. AIDS Behav, 2018; 22(6):1987–2001; doi: 10.1007/s10461-017-1781-y
58.
NgureK, FriedlandBA, SzydloDW, et al.Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLoS One, 2023; 18(6):e0287525; doi: 10.1371/journal.pone.0287525
NunnallyJC. Psychometric Theory. 2d ed. McGraw-Hill: New York; 1978.
62.
DeVellisR. Scale Development: Theory and Applications. SAGE Publications Inc; 2003; pp. 1–113.
63.
TerweeCB, BotSDM, de BoerMR, et al.Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol, 2007; 60(1):34–42; doi: 10.1016/j.jclinepi.2006.03.012
64.
StanglAL, LillestonP, MathemaH, et al.; HPTN 071 (PopART) Study Team. Development of parallel measures to assess HIV stigma and discrimination among people living with HIV, community members and health workers in the HPTN 071 (PopART) trial in Zambia and South Africa. J Int AIDS Soc, 2019; 22(12):e25421; doi: 10.1002/jia2.25421
65.
LiuAY, YangQ, HuangY, et al.Strong relationship between oral dose and tenofovir hair levels in a randomized trial: Hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One, 2014; 9(1):e83736; doi: 10.1371/journal.pone.0083736
66.
GandhiM, GliddenDV, LiuA, et al.; iPrEx Study Team. Strong correlation between concentrations of Tenofovir (TFV) Emtricitabine (FTC) in hair and TFV Diphosphate and FTC Triphosphate in dried blood spots in the iPrEx open label extension: Implications for pre-exposure prophylaxis adherence monitoring. J Infect Dis, 2015; 212(9):1402–1406; doi: 10.1093/infdis/jiv239
67.
KalichmanS, KatnerH, BanasE, et al.Population density and AIDS-related stigma in large-urban, small-urban and rural communities of the Southeastern United States. Prev Sci, 2017; 18(5):517–525; doi: 10.1007/s11121-017-0761-9
68.
GonzalezA, MillerCT, SolomonSE, et al.Size matters: Community size, HIV stigma, & gender differences. AIDS Behav, 2009; 13(6):1205–1212; doi: 10.1007/s10461-008-9465-2
69.
dos SantosMM, KrugerP, MellorsSE, et al.An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: The people living with HIV stigma index. BMC Public Health, 2014; 14(1):80; doi: 10.1186/1471-2458-14-80
70.
StanglAL, LloydJK, BradyLM, et al.A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: How far have we come? J Int AIDS Soc, 2013; 16(3 Suppl 2):18734; doi: 10.7448/IAS.16.3.18734
71.
ScorgieF, KhozaN, BaronD, et al.; EMPOWER study team. Disclosure of PrEP use by young women in South Africa and Tanzania: Qualitative findings from a demonstration project. Cult Health Sex, 2021; 23(2):257–272; doi: 10.1080/13691058.2019.1703041
72.
Van GerwenOT, YigitI, CrockettKB, et al.The relationship between HIV pre-exposure prophylaxis stigma and treatment adherence among current HIV Pre-exposure prophylaxis users in the Southeastern U.S. AIDS Behav, 2023; 27(5):1478–1485; doi: 10.1007/s10461-022-03883-3
73.
ZiaY, EtyangL, MwangiM, et al.; PrEDIRA team. The effect of stigma on family planning and HIV pre-exposure prophylaxis decisions of young women accessing post-abortion care in Kenya. AIDS Behav, 2024; 28(6):1834–1844; doi: 10.1007/s10461-024-04274-6
74.
MusinguziN, PyraM, BukusiEA, et al.; MPYA Study Team. Trajectories of oral PrEP adherence among young Kenyan Women : Implications for promoting effective PrEP use. AIDS Behav, 2023; 27(1):171–181.
75.
NgureK, BrowneEN, ReddyK, et al.Correlates of adherence to oral and vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) participating in the MTN-034/REACH trial. AIDS Behav, 2024; 28(9):2990–3000; doi: 10.1007/s10461-024-04382-3
76.
EarnshawVA, ChaudoirSR. From conceptualizing to measuring HIV stigma: A review of HIV stigma mechanism measures. AIDS Behav, 2009; 13(6):1160–1177; doi: 10.1007/s10461-009-9593-3
77.
EarnshawVA, SmithLR, ChaudoirSR, et al.HIV stigma mechanisms and well-being among PLWH: A test of the HIV stigma framework. AIDS Behav, 2013; 17(5):1785–1795; doi: 10.1007/s10461-013-0437-9
78.
HatzenbuehlerML, Nolen-HoeksemaS, EricksonSJ. Minority stress predictors of HIV risk behavior, substance use, and depressive symptoms: Results from a prospective study of bereaved gay men. Health Psychol, 2008; 27(4):455–462; doi: 10.1037/0278-6133.27.4.455
79.
KempCG, LipiraL, HuhD, et al.HIV stigma and viral load among African-American women receiving treatment for HIV. AIDS, 2019; 33(9):1511–1519.
80.
TuranB, RiceWS, CrockettKB, et al.Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV: The mediating role of depression. AIDS, 2019; 33(3):571–576; doi: 10.1097/QAD.0000000000002071
81.
PergerT, DavtyanM, FosterC, et al.Impact of HIV-related stigma on antiretroviral therapy adherence, engagement and retention in HIV care, and transition to adult HIV care in pediatric and young adult populations living with HIV: A literature review. AIDS Behav, 2025; 29(2):497–516; doi: 10.1007/s10461-024-04534-5
82.
RousseauE, KatzAWK, O’RourkeS, et al.Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE, 2021; 16(10):e0258542–e18; doi: 10.1371/journal.pone.0258542
83.
LoutfyM, TharaoW, LogieC, et al.Systematic review of stigma reducing interventions for African/Black diasporic women. J Int AIDS Soc, 2015; 18(1):19835; doi: 10.7448/IAS.18.1.19835
84.
NybladeL, StanglA, WeissE, et al.Combating HIV stigma in health care settings: What works? J Int AIDS Soc, 2009; 12:15; doi: 10.1186/1758-2652-12-15
85.
BirbeckGL, BondV, EarnshawV, et al.Advancing health equity through cross-cutting approaches to health-related stigma. BMC Med, 2019; 17(1):40; doi: 10.1186/s12916-019-1282-0
86.
BohrenMA, CoronaMV, OdiaseOJ, et al.Strategies to reduce stigma and discrimination in sexual and reproductive healthcare settings: A mixed-methods systematic review. PLOS Glob Public Health, 2022; 2(6):e0000582; doi: 10.1371/journal.pgph.0000582
87.
HartogK, HubbardCD, KrouwerAF, et al.Stigma reduction interventions for children and adolescents in low- and middle-income countries: Systematic review of intervention strategies. Soc Sci Med, 2020; 246:112749; doi: 10.1016/j.socscimed.2019.112749
88.
BaronD, ScorgieF, RamskinL, et al.; EMPOWER study team. “you talk about problems until you feel free”: South African adolescent girls’ and young women’s narratives on the value of HIV prevention peer support clubs. BMC Public Health, 2020; 20(1):1016; doi: 10.1186/s12889-020-09115-4
89.
RobertsST, MancusoN, WilliamsK, et al.How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: A mixed methods analysis. J Int AIDS Soc, 2023; 26(11):e26189; doi: 10.1002/jia2.26189
90.
AgotK, HartmannM, OttichaS, et al.“I didn’t support PrEP because I didn’t know what it was”: Inadequate information undermines male partner support for young women’s pre-exposure prophylaxis use in western Kenya. Afr J AIDS Res, 2022; 21(3):221–230; doi: 10.2989/16085906.2022.2049831
91.
RobertsST, HartmannM, MinnisAM, et al.Breaking down relationship barriers to increase PrEP uptake and adherence among adolescent girls and young women in Kenya: Safety and preliminary effectiveness results from a pilot cluster-randomized trial. J Int AIDS Soc, 2023; 26(12):e26198; doi: 10.1002/jia2.26198
92.
AndersonPL, GliddenDV, LiuA, et al.; iPrEx Study Team. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med, 2012; 4(151):151ra125; doi: 10.1126/scitranslmed.3004006
93.
GrantRM, AndersonPL, McMahanV, et al.; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis, 2014; 14(9):820–829; doi: 10.1016/S1473-3099(14)70847-3
